Results 91 to 100 of about 10,977 (244)

Risks associated with long-term use of proton pump inhibitors [PDF]

, 2017
Proton pump inhibitors (PPIs) are widely used in the management of upper gastrointestinal disorders. In recent years, concerns have been raised on the potential adverse effects of long-term PPI use.
Azzopardi, Neville, Brincat, Anthea
core  

Zollinger-Ellison Syndrome: A Narrative Review of Clinical Presentation, Pathogenesis, Diagnosis and Modern Management Approaches [PDF]

Journal of Clinical and Diagnostic Research
Zollinger-Ellison Syndrome (ZES) is rare disorder which is caused by gastrin-secreting neuroendocrine tumours known as gastrinomas, primarily located in the duodenum or pancreas.
Jaideep Reddy, Raju Shinde, Khushbu Vaidya, Prithvansh Malhotra, Bhagyesh Sapkale   +4 more
doaj   +1 more source

Zollinger–Ellison Syndrome

Video Journal and Encyclopedia of GI Endoscopy, 2014
Abstract Background Zollinger–Ellison (ZE) syndrome is characterized by gastric acid hypersecretion and ulcer disease from autologous gastrin secretion by a gastrinoma. Patient and methods A 43 year old man underwent upper endoscopy for a 6 week history of recurrent nausea, vomiting, heartburn, weight loss, and watery diarrhea. Results Endoscopic
Tang, Shou-jiang, Wu, Ruonan, Bhaijee, Feriyl   +2 more
openaire   +1 more source

Online support groups: an overlooked resource for patients [PDF]

, 2005
Online support groups: history, research, and ...
Potts, HWW
core  

Cutaneous lesions associated to multiple endocrine neoplasia syndrome type 1 [PDF]

, 2008
Original article[Abstract] Background  Multiple endocrine neoplasia type 1 (MEN1) is a genetic disease that predisposes to endocrine tumour development. Some cutaneous lesions (angiofibromas, collagenomas, melanosis guttaca, lipomas, melanomas, ‘cafe
Cordido, Fernando, Fernández, B., Fonseca, E., Iglesias, M.J., Vidal, A.   +4 more
core   +2 more sources

Current Concepts on Gastric Carcinoid Tumors

Gastroenterology Research and Practice, 2012
Gastric carcinoid tumors (GCs) are rare lesions representing less than 10% of carcinoid tumors and less than 1% of all stomach neoplasms. There are three distinct types of gastric carcinoids; type I includes the vast majority (70–85%) of these neoplasms ...
George C. Nikou, Theodoros P. Angelopoulos   +1 more
doaj   +1 more source

Balancing therapeutic benefits and hidden risks of proton pump inhibitors in pediatric practice: a narrative review and update [PDF]

Clinical and Experimental Pediatrics
Proton pump inhibitors (PPIs) are drugs whose main effect is catalytic and long-lasting suppression of gastric acid secretion, with an anti-inflammatory effect.
Maria Rogalidou, Alexandra Papadopoulou
doaj   +1 more source

Getting your report seen in and beyond ABE&M [PDF]

, 2008
Universidade Federal de São Paulo (UNIFESP), Escola Paulista de Medicina (EPM) Department of BiochemistryUNIFESP, EPM, Department of ...
Dias-da-Silva, Magnus Régios
core   +2 more sources

Review: A clinical guide to using intravenous proton-pump inhibitors in reflux and peptic ulcers

Therapeutic Advances in Gastroenterology, 2010
Intravenous (IV) proton-pump inhibitors (PPIs) are potent gastric acid suppressing agents, and their use is popular in clinical practice. Both IV and oral PPIs have similarly short half-lives, and their effects on acid secretion are similar, thus their ...
Sandy H. Pang, David Y. Graham
doaj   +1 more source

Absence of gastrointestinal infections in a cohort of patients with Zollinger-Ellison syndrome and other acid hypersecretors receiving long-term acid suppression with lansoprazole

BMC Gastroenterology, 2008
Background The relationship between proton pump inhibitor therapy and other acid suppressing medications and the risk of gastrointestinal infections remains controversial.
Worthington Julie, Mohnen Jean, Phadnis Milind, Martin Toni, Wilcox C Mel, Hirschowitz Basil I   +5 more
doaj   +1 more source